Short description
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics.
Description
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development.
The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases.
The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.
Last funding
Noaccess
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
San Diego, California, United States, North America
Founded on
January 1, 2005
Exited on
May 15, 2015
Went public on
May 15, 2015
Stock symbol
LIFE
Non-profit?
No
Acquired?
No
Employees count
51-100
Revenue range
$1230 - 4560
Sign in for full access
Investors
Noaccess, Absolutely Noaccess, Uh Ohhhh, Uh Ohhhh, Noway Youcantaccess, Noaccessforu, Cannot Access, No Way, No Way, No Way, Nopepepe, Cannot Access, Uh Ohhhh, Noaccess, No Way, Noway Youcantaccess, Uh Ohhhh, No Way
Sign in for full access
Founders
Paul Schimmel, Xiang-Lei Yang